D. Vecchio, M. , D. Guardo, L. Ascierto, and P. , Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma, European Journal of Cancer, vol.50, issue.1, pp.121-127, 2013.
DOI : 10.1016/j.ejca.2013.09.007

M. Postow, J. Luke, and M. Bluth, Ipilimumab for Patients With Advanced Mucosal Melanoma, The Oncologist, vol.18, issue.6, pp.726-732, 2013.
DOI : 10.1634/theoncologist.2012-0464
URL : http://theoncologist.alphamedpress.org/content/18/6/726.full.pdf

A. Shoushtari, R. Munhoz, and D. Kuk, The efficacy of anti-PD-1 agents in acral and mucosal melanoma, Cancer, vol.523, issue.21, pp.3354-3362, 2016.
DOI : 10.1038/nature14404
URL : http://europepmc.org/articles/pmc5134420?pdf=render

S. Angelo, J. Larkin, and J. Sosman, Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis, J Clin Oncol, vol.35, pp.226-235, 2017.

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 2009.
DOI : 10.1016/j.ejca.2008.10.026

J. Wolchok, A. Hoos, O. Day, and S. , Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7420, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624